Atea Pharmaceuticals (AVIR) Competitors $3.06 -0.06 (-1.92%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.06 +0.00 (+0.16%) As of 10/17/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. CRMD, ANAB, PHAT, TNGX, AVXL, PRME, IOVA, ABUS, XNCR, and KURAShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include CorMedix (CRMD), AnaptysBio (ANAB), Phathom Pharmaceuticals (PHAT), Tango Therapeutics (TNGX), Anavex Life Sciences (AVXL), Prime Medicine (PRME), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Xencor (XNCR), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors CorMedix AnaptysBio Phathom Pharmaceuticals Tango Therapeutics Anavex Life Sciences Prime Medicine Iovance Biotherapeutics Arbutus Biopharma Xencor Kura Oncology CorMedix (NASDAQ:CRMD) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations. Which has more volatility & risk, CRMD or AVIR? CorMedix has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Which has better earnings & valuation, CRMD or AVIR? CorMedix has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M18.28-$17.93M$0.7513.57Atea PharmaceuticalsN/AN/A-$168.38M-$1.61-1.90 Do insiders and institutionals believe in CRMD or AVIR? 34.2% of CorMedix shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 5.3% of CorMedix shares are held by insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer CRMD or AVIR? In the previous week, CorMedix had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 1 mentions for CorMedix and 0 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.00 beat CorMedix's score of -0.07 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment CorMedix Neutral Atea Pharmaceuticals Neutral Is CRMD or AVIR more profitable? CorMedix has a net margin of 42.11% compared to Atea Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 42.73% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CorMedix42.11% 42.73% 34.19% Atea Pharmaceuticals N/A -32.55%-30.47% Do analysts rate CRMD or AVIR? CorMedix presently has a consensus price target of $18.00, indicating a potential upside of 76.82%. Atea Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 96.08%. Given Atea Pharmaceuticals' higher probable upside, analysts plainly believe Atea Pharmaceuticals is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.70Atea Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryCorMedix beats Atea Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$242.84M$3.44B$6.19B$10.56BDividend YieldN/A2.27%5.70%4.81%P/E Ratio-1.9023.0185.5427.13Price / SalesN/A481.75608.39130.24Price / CashN/A46.9237.1060.81Price / Book0.5910.4112.236.52Net Income-$168.38M-$52.77M$3.33B$276.93M7 Day Performance-2.55%2.31%1.17%1.93%1 Month Performance6.25%12.59%6.85%2.19%1 Year Performance-19.90%11.18%58.93%34.62% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals1.8063 of 5 stars$3.06-1.9%$6.00+96.1%-19.9%$242.84MN/A-1.9070CRMDCorMedix3.282 of 5 stars$11.56+1.9%$18.00+55.7%-7.5%$885.19M$43.47M15.4130ANABAnaptysBio2.8554 of 5 stars$30.25-2.2%$48.75+61.2%-1.0%$866.23M$123.16M-6.75100Trending NewsAnalyst ForecastAnalyst RevisionPHATPhathom Pharmaceuticals2.9641 of 5 stars$11.61-4.9%$17.50+50.7%-19.4%$866.22M$55.25M-2.45110News CoverageAnalyst UpgradeTNGXTango Therapeutics1.5388 of 5 stars$7.58-2.3%$10.50+38.5%+21.0%$863.38M$42.07M-5.7090AVXLAnavex Life Sciences3.1774 of 5 stars$9.61-3.5%$44.00+357.9%+58.9%$855.50MN/A-16.8640PRMEPrime Medicine0.703 of 5 stars$6.08-3.8%N/AN/A$850.51M$2.98M-3.90N/AGap DownIOVAIovance Biotherapeutics4.2705 of 5 stars$2.21-5.6%$11.90+438.5%-78.7%$846.74M$241.53M-1.80500News CoverageGap DownABUSArbutus Biopharma2.1481 of 5 stars$4.34-0.9%$5.00+15.2%+6.3%$839.64M$15.42M-14.9790News CoverageXNCRXencor3.7061 of 5 stars$11.79+0.2%$24.22+105.4%-32.2%$839.47M$146.93M-4.91280News CoverageAnalyst ForecastKURAKura Oncology4.1507 of 5 stars$9.80+2.4%$24.10+145.9%-45.3%$830.65M$83.28M-4.34130Gap Down Related Companies and Tools Related Companies CorMedix Alternatives AnaptysBio Alternatives Phathom Pharmaceuticals Alternatives Tango Therapeutics Alternatives Anavex Life Sciences Alternatives Prime Medicine Alternatives Iovance Biotherapeutics Alternatives Arbutus Biopharma Alternatives Xencor Alternatives Kura Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVIR Stock Alerts